Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
244
-
Total 13F shares, excl. options
-
67,877,270
-
Shares change
-
+450,744
-
Total reported value, excl. options
-
$7,730,039,829
-
Value change
-
+$45,641,218
-
Put/Call ratio
-
38%
-
Number of buys
-
121
-
Number of sells
-
-126
-
Price
-
$113.86
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2021
294 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2021.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 244 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67,877,270 shares
of 95,963,102 outstanding shares and own 70.73% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (10,671,786 shares), Capital Research Global Investors (7,373,873 shares), VANGUARD GROUP INC (5,889,465 shares), BlackRock Inc. (5,462,185 shares), Capital International Investors (5,424,122 shares), FEDERATED HERMES, INC. (3,912,408 shares), Capital World Investors (2,766,905 shares), Clearbridge Investments, LLC (1,903,395 shares), STATE STREET CORP (1,610,839 shares), and ALKEON CAPITAL MANAGEMENT LLC (1,313,857 shares).
This table shows the top 244 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.